Please use this identifier to cite or link to this item: doi:10.22028/D291-37161
Title: ADAM8 signaling drives neutrophil migration and ARDS severity
Author(s): Conrad, Catharina
Yildiz, Daniela
Cleary, Simon J.
Margraf, Andreas
Cook, Lena
Schlomann, Uwe
Panaretou, Barry
Bowser, Jessica L.
Karmouty-Quintana, Harry
Li, Jiwen
Berg, Nathaniel K.
Martin, Samuel C.
Aljohmani, Ahmad
Moussavi-Harami, S. Farshid
Wang, Kristin M
Tian, Jennifer J.
Magnen, Mélia
Valet, Colin
Qiu, Longhui
Singer, Jonathan P.
Eltzschig, Holger K.
Bertrams, Wilhelm
Herold, Susanne
Suttorp, Norbert
Schmeck, Bernd
Ball, Zachary T.
Zarbock, Alexander
Looney, Mark R.
Bartsch, Jörg W.
Language: English
Title: JCI insight
Volume: 7
Issue: 3
Publisher/Platform: American Society for Clinical Investigation
Year of Publication: 2022
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Acute respiratory distress syndrome (ARDS) results in catastrophic lung failure and has an urgent, unmet need for improved early recognition and therapeutic development. Neutrophil influx is a hallmark of ARDS and is associated with the release of tissue-destructive immune effectors, such as matrix metalloproteinases (MMPs) and membrane-anchored metalloproteinase disintegrins (ADAMs). Here, we observed using intravital microscopy that Adam8–/– mice had impaired neutrophil transmigration. In mouse pneumonia models, both genetic deletion and pharmacologic inhibition of ADAM8 attenuated neutrophil infiltration and lung injury while improving bacterial containment. Unexpectedly, the alterations of neutrophil function were not attributable to impaired proteolysis but resulted from reduced intracellular interactions of ADAM8 with the actin-based motor molecule Myosin1f that suppressed neutrophil motility. In 2 ARDS cohorts, we analyzed lung fluid proteolytic signatures and identified that ADAM8 activity was positively correlated with disease severity. We propose that in acute inflammatory lung diseases such as pneumonia and ARDS, ADAM8 inhibition might allow fine-tuning of neutrophil responses for therapeutic gain.
DOI of the first publication: 10.1172/jci.insight.149870
URL of the first publication: https://insight.jci.org/articles/view/149870
Link to this record: urn:nbn:de:bsz:291--ds-371611
hdl:20.500.11880/33721
http://dx.doi.org/10.22028/D291-37161
ISSN: 2379-3708
Date of registration: 6-Sep-2022
Description of the related object: Supplemental material
Related object: https://insight.jci.org/articles/view/149870/sd/1
https://insight.jci.org/articles/view/149870/sd/2
https://insight.jci.org/articles/view/149870/sd/3
Faculty: M - Medizinische Fakultät
Department: M - Experimentelle und Klinische Pharmakologie und Toxikologie
Professorship: M - Jun.-Prof. Dr. Daniela Yildiz
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
149870.1-20220120113113-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf8,44 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons